Genocea To Host First Quarter 2021 Corporate Update Conference Call & Webcast

Rhea-AI Summary

Genocea Biosciences (NASDAQ: GNCA) is set to announce its first quarter 2021 financial results and provide a corporate update on April 29, 2021, at 8:30 a.m. ET. Interested parties can join the conference call by dialing (844) 826-0619 (domestic) or (315) 625-6883 (international) with conference ID 2191366. A live audio webcast will also be available on their investor relations webpage. Genocea is focused on developing immunotherapies for cancer, utilizing its proprietary ATLAS™ platform, and currently advancing two clinical trials for its neoantigen vaccine and adoptive T cell therapy.

CAMBRIDGE, Mass., April 22, 2021 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, will host its first quarter 2021 financial results and corporate update conference call and live audio webcast on Thursday, April 29 at 8:30 a.m. ET.

Interested participants may access the conference call by dialing (844) 826-0619 (domestic) or (315) 625-6883 (international) and referring to conference ID number 2191366. To join the live webcast, please visit the presentation page of the investor relations section of the Genocea website at https://ir.genocea.com/events-presentations.

A webcast replay will be available on the Genocea website beginning approximately two hours after the event and will be archived for 90 days.

About Genocea Biosciences, Inc.
Genocea’s mission is to identify the right tumor targets to develop life-changing immunotherapies for people suffering from cancer. Our proprietary ATLAS™ platform comprehensively profiles each patient’s T cell responses to potential targets, or antigens, on that patient’s tumor. ATLAS zeroes in on both antigens that activate anti-tumor T cell responses and inhibitory antigens, Inhibigens™, that drive pro-tumor immune responses. We are advancing two ATLAS-enabled programs: GEN-009, our neoantigen vaccine for which we are conducting a Phase 1/2a clinical trial and GEN-011, our adoptive T cell therapy using neoantigen-targeted peripheral cells for which we are commencing a Phase 1/2a clinical trial. In addition to our two clinical programs, we are conducting research in several areas where we believe ATLAS could be a key tool in identifying meaningful therapies. To learn more, please visit https://www.genocea.com.

Investor Contact:
Dan Ferry
617-430-7576
daniel@lifesciadvisors.com

FAQ

What is the date and time of the Genocea Biosciences Q1 2021 financial results call?

The Genocea Biosciences Q1 2021 financial results call is scheduled for April 29, 2021, at 8:30 a.m. ET.

How can I access the Genocea Biosciences conference call?

You can access the Genocea Biosciences conference call by dialing (844) 826-0619 for domestic calls or (315) 625-6883 for international calls, using conference ID 2191366.

Where can I find the Genocea Biosciences Q1 financial results webcast?

The webcast for the Genocea Biosciences Q1 financial results can be found on the investor relations section of their website at https://ir.genocea.com/events-presentations.

What are the main clinical programs Genocea Biosciences is working on?

Genocea Biosciences is advancing two clinical programs: GEN-009, a neoantigen vaccine in Phase 1/2a clinical trial, and GEN-011, an adoptive T cell therapy also in Phase 1/2a clinical trial.

What is the ATLAS™ platform developed by Genocea Biosciences?

The ATLAS™ platform is used by Genocea Biosciences to profile T cell responses to tumor antigens, identifying both anti-tumor responses and inhibitory responses to develop immunotherapies.